🩺✅CVRX — Watching the adoption curve build, one implant at a time

Scrolling through CVRx's recent updates, the pattern is hard to miss: new hospitals picking up Barostim almost every week, and existing centers hitting real milestones — 10th, 25th, even 50th implants. Sarasota Memorial, Baylor Scott & White, Springhill Medical Center, USA Health, M Health Fairview at the University of Minnesota — the geographic footprint keeps widening across the U.S., and it's not limited to the U.S. either, with centers in Germany now onboarding as well.

The reimbursement backdrop keeps getting stronger too. Barostim carries full FDA 🚀approval for heart failure patients in the U.S., plus CE Mark approval in the European Economic Area. On the payer side, Medicare has steadily improved how it treats the procedure — better inpatient payment classification, a move to Category I CPT codes that puts it on the same institutional footing as other established therapies, and continued favorable outpatient payment decisions from CMS. Add recent wins ✅with Medicare Advantage plans like Humana, and the reimbursement path for hospitals adopting Barostim looks increasingly well-paved.

New clinical publications are showing up alongside the implant milestones too — recent data on ambulatory hemodynamic improvements and reduced diuretic needs in heart failure patients add to a growing evidence base that supports what these hospitals are seeing firsthand.

Taken together, it's a steady, expanding footprint backed by a strengthening reimbursement environment — the kind of quiet, cumulative progress worth keeping an eye on.